Literature DB >> 15536603

Insulin regulation of free fatty acid kinetics in adult cystic fibrosis patients with impaired glucose tolerance.

Antoinette Moran1, Rita Basu, Carlos Milla, Michael D Jensen.   

Abstract

Cystic fibrosis (CF) patients are insulin-resistant with regards to suppression of hepatic glucose production and proteolysis, but the effect of insulin on adipose free fatty acid (FFA) release has not been studied. [9,10-(3)H]palmitate kinetics were measured in 11 stable adult CF patients with impaired glucose tolerance (IGT) and 9 normal control subjects. Baseline plasma palmitate concentrations [CF = 99 +/- 13 (median 74, range 65 to 187); control = 88 +/- 9 (88, 46 to 138) micromol/L, P = .9] and palmitate flux [CF = 114 +/- 11 (100, 72 to 171); control = 105 +/- 12 (106, 54 to 182) micromol/min, P = 0.9] were not different between CF patients and controls. During a euglycemic clamp with infusion of insulin to physiologic postprandial levels, however, palmitate concentrations tended to be higher in CF patients: CF = 18 +/- 3 (13, 10 to 47), control = 12 +/- 1 (11, 8 to 18) micromol/L, P = 0.08. The higher palmitate concentrations during hyperinsulinemia appeared to be due to reduced suppression of adipose tissue palmitate release, because mean palmitate flux was 33% greater in CF subjects [32 +/- 5 (26, 17 to 66) micromol/min] than controls: [24 +/- 2 (23, 17 to 34) micromol/min], P = .20. There was considerably greater heterogeneity in insulin-induced suppression of plasma palmitate concentration and flux in CF patients compared to normal control subjects. In summary, a defect in insulin suppression of lipolysis was seen in clinically stable CF patients with IGT, similar to what has been described in CF for amino acid and glucose metabolism. This quantitative difference in lipolysis may account for inadequate insulin-induced suppression of hepatic glucose production in CF, and may be a metabolic adaptation to increased energy needs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15536603     DOI: 10.1016/j.metabol.2004.06.015

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  Oral glucose tolerance testing in children with cystic fibrosis.

Authors:  Katie Larson Ode; Brigitte Frohnert; Theresa Laguna; James Phillips; Bonnie Holme; Warren Regelmann; William Thomas; Antoinette Moran
Journal:  Pediatr Diabetes       Date:  2010-11       Impact factor: 4.866

2.  Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex.

Authors:  Connor Lewis; Scott M Blackman; Amanda Nelson; Ewa Oberdorfer; Daniel Wells; Jordan Dunitz; William Thomas; Antoinette Moran
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

3.  Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial.

Authors:  Antoinette Moran; Penelope Pekow; Patricia Grover; Martha Zorn; Bonnie Slovis; Joseph Pilewski; Elizabeth Tullis; Theodore G Liou; Holley Allen
Journal:  Diabetes Care       Date:  2009-07-10       Impact factor: 17.152

4.  Impaired fasting glucose in cystic fibrosis.

Authors:  Brigitte I Frohnert; Katie Larson Ode; Antoinette Moran; Brandon M Nathan; Theresa Laguna; Bonnie Holme; William Thomas
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

Review 5.  Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Authors:  Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

Review 6.  Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis.

Authors:  Oranan Siwamogsatham; Jessica A Alvarez; Vin Tangpricha
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

7.  Glargine versus NPH insulin in cystic fibrosis related diabetes.

Authors:  Patricia Grover; William Thomas; Antoinette Moran
Journal:  J Cyst Fibros       Date:  2007-08-09       Impact factor: 5.482

Review 8.  The cystic fibrosis transmembrane recruiter the alter ego of CFTR as a multi-kinase anchor.

Authors:  Anil Mehta
Journal:  Pflugers Arch       Date:  2007-09-06       Impact factor: 3.657

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.